Host: John Buse, MD, PhD <br>

Guest: Antonios Douros, MD <br>


  <p>Dr. John Buse joins Dr. Antonios Douros, Assistant Professor in the Department of Medicine at McGill University and research investigator at Lady Davis Institute in Montreal, Quebec, to discuss his latest research focusing on SGLT2 inhibitors and diabetic ketoacidosis risk.</p>

Host: John Buse, MD, PhD Guest: Antonios Douros, MD Dr. John Buse joins Dr. Antonios Douros, Assistant Professor in the Department of Medicine at McGill University and research investigator at Lady Davis Institute in Montreal, Quebec, to discuss his latest research focusing on SGLT2 inhibitors and diabetic ketoacidosis risk.

Diving into Diabetes: Investigating SGLT2 Inhibitors & Diabetic Ketoacidosis

As the number of Americans living with diabetes continues to rise, staying up to date on the latest diabetes research is more essential than ever to help patients achieve glucose control. With Diabetes Discourse, you’ll hear from diabetes and endocrinology experts on emerging research, diagnostic and treatment strategies, and various elements that impact a patient’s disease course, including risk factors, vitamin and mineral supplementation, physical activity, and kidney disease.
Because when it comes to diabetes, glucose control is just the beginning.

Medicine

As the number of Americans living with diabetes continues to rise, staying up to date on the latest diabetes research is more essential than ever to help patients achieve glucose control. With Diabetes Discourse, you’ll hear from diabetes and endocrinology experts on emerging research, diagnostic and treatment strategies, and various elements that impact a patient’s disease course, including risk factors, vitamin and mineral supplementation, physical activity, and kidney disease. Because when it comes to diabetes, glucose control is just the beginning.

Share Diving into Diabetes: Investigating SGLT2 Inhibitors & Diabetic Ketoacidosis

Sign up to save your podcasts

Diving into Diabetes: Investigating SGLT2 Inhibitors & Diabetic Ketoacidosis

Diving into Diabetes: Investigating SGLT2 Inhibitors & Diabetic Ketoacidosis